Sponsors (7)
Divides NIAID into three separate NIH institutes, reorganizes statute and leadership, and establishes five-year presidential terms for new institute directors.
Official title: To replace the National Institute of Allergy and Infectious Diseases with 3 separate national research institutes.
Introduced February 21, 2025 by Charles Roy · Last progress February 21, 2025
The bill reorganizes infectious, allergic, and immunologic research into separate institutes to sharpen research focus and strengthen public-health preparedness, but it raises costs and creates short-term disruption and risks of politicized or less-continuous leadership.
Patients, hospitals, and the public benefit from improved public-health preparedness because infectious-disease authorities are consolidated into a dedicated National Institute of Infectious Diseases, which could enhance outbreak response and coordination.
Scientists and researchers gain more focused institutes for allergy, infectious, and immunologic research, which should increase targeted research funding and scientific attention to those areas.
State governments, hospitals, and research grantees face clearer statutory organization and streamlined authority transfers, reducing administrative confusion and improving grant and program management.
Taxpayers and researchers may face higher administrative costs or fewer resources for existing projects because creating three new institutes increases overhead or could reallocate research funds.
Scientists, hospitals, and research partners could see short-term disruption to ongoing research programs, grants, and collaborations as authorities and statutes are reassigned during the transition.
Federal employees and the research community risk politicization and leadership instability because the current NIAID Director is terminated and new institute directors require Presidential appointment, which could inject political considerations into research leadership.
Based on analysis of 2 sections of legislative text.
Splits the National Institute of Allergy and Infectious Diseases (NIAID) into three separate institutes—Allergic Diseases, Infectious Diseases, and Immunologic Diseases—by amending the Public Health Service Act and reorganizing statutory provisions. It ends the current NIAID director position at enactment, places interim oversight with the NIH Director, and establishes five-year presidential appointment terms (one reappointment allowed) for each new institute director, with many conforming statutory cross-references updated.